Article
Gastroenterology & Hepatology
Marina Liso, Giulio Verna, Elisabetta Cavalcanti, Stefania De Santis, Raffaele Armentano, Angela Tafaro, Antonio Lippolis, Pietro Campiglia, Antonio Gasbarrini, Mauro Mastronardi, Theresa Torres Pizarro, Fabio Cominelli, Loris Riccardo Lopetuso, Marcello Chieppa
Summary: This study provides new insights and alternative approaches to treat ulcerative colitis (UC) patients. It suggests that anti-interleukin (IL)1 strategies, such as anakinra, may be a more effective therapeutic option for primary nonresponders to anti-tumor necrosis factor (TNF) therapy.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Kengo Kanayama, Jun Kato, Wataru Shiratori, Ariki Nagashima, Yuki Ohta, Takashi Taida, Keiko Saito, Chihiro Goto, Satsuki Takahashi, Ryosuke Horio, Akane Kurosugi, Tsubasa Ishikawa, Tatsuya Kaneko, Naoki Akizue, Kenichiro Okimoto, Tomoaki Matsumura, Naoya Kato
Summary: This study found that selecting subsequent treatment based on the response to initial anti-tumor necrosis factor (TNF)alpha antibody (ATA) is feasible in refractory ulcerative colitis (UC) patients. Non-ATA may be suitable as subsequent biologics for UC patients regardless of the efficacy of the first ATA.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Gaoxing Ma, Qiuhui Hu, Yanhui Han, Hengjun Du, Wenjian Yang, Che Pan, Xiaoqiong Cao, Benard Muinde Kimatu, Fei Pei, Hang Xiao
Summary: The study demonstrated that WPEP has significant inhibitory effects on colitis, reducing disease activity index, pro-inflammatory cytokine concentrations, and protein expressions, increasing colon length, and improving histology. Furthermore, WPEP affects the accumulation of immune cells and reverses dysbiosis in the gut microbiota of colitic mice.
Article
Health Care Sciences & Services
Laura A. Lucaciu, Maria Ilies, Stefan C. Vesa, Radu Seicean, Shahida Din, Cristina Adela Iuga, Andrada Seicean
Summary: Interleukin (IL)-23 and fecal calprotectin levels were significantly elevated in severe inflammatory bowel disease (IBD), while IL-17 and C-reactive protein were associated with disease severity. IL-23 may serve as a promising novel biomarker for severe Crohn's disease, guiding clinical decision-making on biologic therapy. Identifying the main IL pathway involved in IBD severity could provide valuable insights for personalized treatment approaches.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Review
Immunology
Marie Robert, Pierre Miossec
Summary: TNF inhibitors have greatly improved the treatment of various diseases but may also increase the risk of latent TB infection. Screening for latent TB infection in patients during treatment is essential for optimal safety.
CELLULAR & MOLECULAR IMMUNOLOGY
(2021)
Article
Gastroenterology & Hepatology
Sun-Ho Lee, Margaret Walshe, Eun Hye Oh, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Tomer Greener, Adam Weizman, Mark S. Silverberg, Byong Duk Ye
Summary: The study suggests that changes in serum albumin levels within the first 2 weeks of anti-TNF treatment can predict primary nonresponse, endoscopic outcomes, time to colectomy, and anti-TNF failure in patients with UC. Early access to this biomarker may help identify patients at risk of treatment failure and guide early optimization of anti-TNF therapy.
INFLAMMATORY BOWEL DISEASES
(2021)
Article
Gastroenterology & Hepatology
Bindu Chandrasekharan, Darra Boyer, Joshua A. Owens, Alexandra A. Wolfarth, Bejan J. Saeedi, Tanvi Dhere, Heba Iskandar, Andrew S. Neish
Summary: Selective blocking of NPY receptors using small molecule antagonists can attenuate intestinal inflammation by lowering TNF levels, suggesting a promising therapeutic value for NPY1R inhibition in alleviating inflammation in ulcerative colitis.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Surgery
J. A. Bunce, B. Doleman, J. N. Lund, G. M. Tierney
Summary: This study investigated the impact of surgeon subspeciality on outcomes after emergency laparotomy for inflammatory bowel disease (IBD). It found that colorectal surgeons had significantly better outcomes in terms of mortality and length of stay for the least urgent category of IBD emergency laparotomies. However, this association was not seen in more urgent cases.
WORLD JOURNAL OF SURGERY
(2023)
Article
Gastroenterology & Hepatology
Ligia Yukie Sassaki, Daniela Oliveira Magro, Rogerio Saad-Hossne, Julio Pinheiro Baima, Cristina Flores, Lucianna Motta Correia, Livia Medeiros Soares Celani, Maria De Lourdes De Abreu Ferrari, Patricia Zacharias, Marley Ribeiro Feitosa, Carlos Henrique Marques Dos Santos, Manoel Alvaro De Freitas Lins Neto, Abel Botelho Quaresma, Sergio Figueiredo De Lima Junior, Graciana Bandeira Salgado De Vasconcelos, Ornella Sari Cassol, Arlene Dos Santos Pinto, Gustavo Kurachi, Francisco de Assis Goncalves Filho, Rodrigo Galhardi Gasparini, Thaisa Kowalski Furlan, Wilson Roberto Catapani, Claudio Saddy Rodrigues Coy, Vivian De Souza Menegassi, Marilia Majeski Colombo, Renata de Sa Brito Froes, Fabio Vieira Teixeira, Antonio Carlos Moraes, Genoile Oliveira Santana, Jose Miguel Luz Parente, Eduardo Garcia Vilela, Natalia Sousa Freitas Queiroz, Paulo Gustavo Kotze
Summary: The study compared clinical and endoscopic remission rates between adalimumab and infliximab in Brazilian UC patients, showing higher remission rates with infliximab. Factors associated with higher clinical remission rates included no prior exposure to biological therapy and early response to anti-TNF treatment.
BMC GASTROENTEROLOGY
(2022)
Article
Pediatrics
Maya Ruban, Adam Slavick, Achiya Amir, Amir Ben-Tov, Hadar Moran-Lev, Yael Weintraub, Adi Anafy, Shlomi Cohen, Anat Yerushalmy-Feler
Summary: The rate of a positive family history of IBD in the pediatric IBD population is increasing, and patients with a positive family history are more likely to have a severe phenotype, receive more nutritional therapy, and less corticosteroids. Patients with a negative family history may require intensified biologic therapy.
EUROPEAN JOURNAL OF PEDIATRICS
(2022)
Review
Medicine, General & Internal
Guanglin Cui, Qingbo Fan, Zhenfeng Li, Rasmus Goll, Jon Florholmen
Summary: This review discusses the use of TNF antibodies in treating IBD and the evaluation of therapeutic efficacy using current and novel biomarkers. It emphasizes the urgent need for validation and comparison studies of promising novel biomarkers to improve their value in clinical practice.
Article
Biochemistry & Molecular Biology
Alexandra Wetzel, Bettina Scholtka, Fabian Schumacher, Harshadrai Rawel, Birte Geisendoerfer, Burkhard Kleuser
Summary: Research has shown that upregulation of EBI3 through histone acetylation can alleviate symptoms in a mouse model of chronic colitis. Further investigation revealed that under inflammatory conditions, treatment with DNA methylation inhibitors and TNF alpha led to synergistic upregulation of EBI3 in human colon epithelial cells. The results suggest that the upregulation of EBI3 under inflammatory and demethylating conditions may lead to the formation of anti-inflammatory IL-35, which could be a potential therapeutic target for colitis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Gastroenterology & Hepatology
Raja Atreya, Markus F. Neurath
Summary: Increasing insights into the immunopathogenesis of inflammatory bowel diseases have led to a wider range of therapeutic options, including secondary biological therapies such as IL-23p19 inhibitors. These inhibitors have shown significant efficacy in patients who do not respond well to primary anti-TNF treatment.
JOURNAL OF CROHNS & COLITIS
(2022)
Article
Cell Biology
Danhua Yao, Zhiyuan Zhou, Pengfei Wang, Lei Zheng, Yuhua Huang, Yantao Duan, Bin Liu, Yousheng Li
Summary: The study demonstrated that miR-125-5p plays a crucial role in ulcerative colitis by targeting IL-6 R, with its up-regulation reducing inflammatory factor expression, cell apoptosis, and inhibiting the activation of JAK1/STAT3 and NF-kappa B pathways. This research suggests that miR-125-5p could serve as a potential therapeutic target for ulcerative colitis.
Article
Pharmacology & Pharmacy
Pengcheng Luo, Yina Wang, Chongqiang Zhao, Junyi Guo, Wei Shi, Haiyan Ma, Tianshu Liu, Dan Yan, Shengqi Huo, Moran Wang, Chenglong Li, Jiayuh Lin, Sheng Li, Jiagao Lv, Cuntai Zhang, Li Lin
Summary: Bazedoxifene effectively attenuated atherosclerotic plaque area and down-regulated IL-6 levels in ApoE-deficient mice, suggesting its potential as a novel therapeutic reagent for atherosclerosis by regulating the IL-6/IL-6R/STAT3 signaling pathway.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Article
Gastroenterology & Hepatology
Gaetano Bergamaschi, Fabiana Castiglione, Renata D'Inca, Marco Astegiano, Walter Fries, Monica Milla, Carolina Ciacci, Fernando Rizzello, Simone Saibeni, Rachele Ciccocioppo, Ambrogio Orlando, Fabrizio Bossa, Mariabeatrice Principi, Piero Vernia, Chiara Ricci, Maria L. Scribano, Giorgia Bodini, Dario Mazzucco, Gabrio Bassotti, Gabriele Riegler, Andrea Buda, Matteo Neri, Flavio Caprioli, Fabio Monica, Aldo Manca, Erica Villa, Gionata Fiorino, Michele Comberlato, Nicola Aronico, Cristina Della Corte, Roberta Caccaro, Paolo Gionchetti, Paolo Giuffrida, Paola Iovino, Marco Lenti, Caterina Mengoli, Lucienne Pellegrini, Alberto Pieraccini, Davide Ribaldone, Anna Testa, Cristina Ubezio, Anna Viola, Maurizio Vecchi, Catherine Klersy, Antonio Di Sabatino
Summary: The prevalence of anemia in Italian IBD patients is lower than previously reported, with the majority being caused by iron deficiency and leading to fatigue and decreased quality of life. However, a large proportion of patients with iron and/or vitamin deficiencies remain untreated.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Claudia Burrello, Francesco Strati, Georgia Lattanzi, Angelica Diaz-Basabe, Erika Mileti, Maria Rita Giuffre, Gianluca Lopez, Fulvia Milena Cribiu, Elena Trombetta, Marinos Kallikourdis, Marco Cremonesi, Francesco Conforti, Fiorenzo Botti, Laura Porretti, Maria Rescigno, Maurizio Vecchi, Massimo C. Fantini, Flavio Caprioli, Federica Facciotti
Summary: This study identified IL-10-producing iNKT cells in the intestine, which demonstrate suppressive capabilities towards pathogenic CD4+ T cells and are associated with better clinical outcomes in Crohn's disease patients. The presence of SCFA-producing bacteria in the gut microbiota sustained the production of IL-10 by iNKT cells, highlighting the important immunoregulatory role of intestinal iNKT cells in maintaining immune homeostasis.
JOURNAL OF CROHNS & COLITIS
(2022)
Review
Gastroenterology & Hepatology
Gaetano Bergamaschi, Flavio Caprioli, Marco Vincenzo Lenti, Luca Elli, Franco Radaelli, Emanuele Rondonotti, Caterina Mengoli, Emanuela Miceli, Chiara Ricci, Sandro Ardizzone, Maurizio Vecchi, Antonio Di Sabatino
Summary: Anemia is a common complication of gastrointestinal disorders, with iron deficiency anemia (IDA) and anemia of inflammation (AI) being the most prevalent forms. This article discusses the pathogenesis of anemia in GI disorders, the distinction between IDA and AI, and various therapeutic and preventive measures. However, there is a lack of large randomized controlled trials on the treatment of anemia in GI disorders.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Marco Vincenzo Lenti, Federica Facciotti, Emanuela Miceli, Alessandro Vanoli, Giulia Fornasa, Edith Lahner, Ilaria Spadoni, Paolo Giuffrida, Giovanni Arpa, Alessandra Pasini, Laura Rovedatti, Flavio Caprioli, Cristina Travelli, Georgia Lattanzi, Laura Conti, Catherine Klersy, Maurizio Vecchi, Marco Paulli, Bruno Annibale, Gino Roberto Corazza, Maria Rescigno, Antonio Di Sabatino
Summary: This study found that plasma cells and proinflammatory cytokines were significantly increased in patients with AAG. TSLP and NAMPT may serve as potential therapeutic targets, while zinc-L-carnosine could alleviate mucosal inflammation.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY
(2022)
Article
Medicine, General & Internal
Francesca Ferretti, Maria Camilla Monico, Rosanna Cannatelli, Stefania Carmagnola, Marco Vincenzo Lenti, Antonio Di Sabatino, Francesco Conforti, Luca Pastorelli, Flavio Caprioli, Cristina Bezzio, Simone Saibeni, Stefano Mazza, Maurizio Vecchi, Giovanni Maconi, Sandro Ardizzone
Summary: This study suggests that the type of biologic treatment may affect the risk of developing extra-intestinal manifestations in patients with inflammatory bowel disease. There is a slightly higher risk in patients on gut-selective therapies, but the clinical course is similar in both groups.
FRONTIERS IN MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Fabio Salvatore Macaluso, Mariabeatrice Principi, Federica Facciotti, Antonella Contaldo, Alessia Todeschini, Simone Saibeni, Cristina Bezzio, Fabiana Castiglione, Olga Maria Nardone, Rocco Spagnuolo, Massimo Claudio Fantini, Gaia Riguccio, Flavio Caprioli, Chiara Vigano, Carla Felice, Gionata Fiorino, Carmen Correale, Giorgia Bodini, Monica Milla, Giulia Scardino, Marta Vernero, Federico Desideri, Mariella Mannino, Giuseppe Rizzo, Ambrogio Orlando
Summary: The study investigated the humoral response to COVID-19 vaccines in patients with inflammatory bowel disease (IBD) treated with immunomodulatory or biological drugs. The majority of IBD patients showed seropositivity after COVID-19 vaccination, but the magnitude of the humoral response was significantly lower compared to healthy controls. These findings suggest that the lower response is mostly unrelated to the use of immune-modifying treatments.
DIGESTIVE AND LIVER DISEASE
(2023)
Article
Gastroenterology & Hepatology
Andrea Cassinotti, Nicolo Mezzina, Annalisa De Silvestri, Dhanai Di Paolo, Marco Vincenzo Lenti, Cristina Bezzio, Davide Stradella, Martina Mauri, Valentina Zadro, Chiara Ricci, Valentina Casini, Elisa Radice, Alessandro Massari, Giovanni Maconi, Simone Saibeni, Flavio Caprioli, Roberto Tari, Maria Fichera, Claudio Camillo Cortelezzi, Marco Parravicini, Carmine Tinelli, Pier Alberto Testoni, Fabio Pace, Sergio Segato, Pietro Invernizzi, Pietro Occhipinti, Gianpiero Manes, Antonio Di Sabatino, Luca Pastorelli, Maurizio Vecchi, Sandro Ardizzone
Summary: This study compared the efficacy of adalimumab, infliximab biosimilar, golimumab, and vedolizumab in the treatment of ulcerative colitis. The results showed that all four biologics had similar rates of clinical remission at one year, while vedolizumab was more effective in patients who had failed previous anti-TNF alpha treatment.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
(2022)
Article
Medicine, Research & Experimental
Andrea Farini, Luana Tripodi, Chiara Villa, Francesco Strati, Amanda Facoetti, Guido Baselli, Jacopo Troisi, Annamaria Landolfi, Caterina Lonati, Davide Molinaro, Michelle Wintzinger, Stefano Gatti, Barbara Cassani, Flavio Caprioli, Federica Facciotti, Mattia Quattrocelli, Yvan Torrente
Summary: Duchenne muscular dystrophy (DMD) is a progressive muscle wasting disease caused by mutations in the DMD gene. In this study, researchers investigated the role of intestinal bacteria in supporting the muscle immune response in a dystrophic mouse model. They found a correlation between DMD disease features and the abundance of Prevotella bacteria. Manipulating the gut microbial community through germ-free animal models and antibiotic treatment influenced muscle immunity and fibrosis. Intestinal colonization with beneficial bacteria improved inflammation, muscle pathology, and function. This study highlights a potential role for the gut microbiota in DMD pathogenesis.
EMBO MOLECULAR MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Fabio Salvatore Macaluso, Claudio Papi, Ambrogio Orlando, Stefano Festa, Daniela Pugliese, Stefanos Bonovas, Claudia Pansieri, Daniele Piovani, Gionata Fiorino, Massimo Claudio Fantini, Flavio Caprioli, Marco Daperno, Alessandro Armuzzi
Summary: A cure for Crohn's disease is currently unavailable, so lifelong management is necessary. Different biological drugs have been approved, including monoclonal antibodies targeting inflammatory pathways and adipose-derived stromal cells for perianal fistula. Italian guidelines on the use of biologics for managing CD have been issued, providing recommendations for different clinical settings. The recommendations are based on evidence from real world studies.
DIGESTIVE AND LIVER DISEASE
(2023)
Meeting Abstract
Gastroenterology & Hepatology
F. Bossa, M. Guerra, S. Carparelli, M. Antonella, F. Terracciano, A. Costantino, F. Caprioli, M. R. Valvano, G. Martino, M. Nardella, F. Perri
JOURNAL OF CROHNS & COLITIS
(2022)
Meeting Abstract
Gastroenterology & Hepatology
F. Bossa, M. Guerra, S. Carparelli, M. Antonella, F. Terracciano, A. Costantino, F. Caprioli, M. R. Valvano, G. Martino, M. Nardella, F. Perri
JOURNAL OF CROHNS & COLITIS
(2022)
Meeting Abstract
Gastroenterology & Hepatology
A. Costantino, M. Vecchi, D. Stocco, D. Noviello, F. S. Conforti, M. Maregatti, F. Caprioli
JOURNAL OF CROHNS & COLITIS
(2022)
Meeting Abstract
Gastroenterology & Hepatology
A. Costantino, M. Vecchi, D. Stocco, D. Noviello, F. S. Conforti, M. Maregatti, F. Caprioli
JOURNAL OF CROHNS & COLITIS
(2022)
Meeting Abstract
Gastroenterology & Hepatology
A. Costantino, F. Caprioli, M. Vecchi, D. Stocco, M. Aloi, A. Armuzzi, F. Ficari, F. Manguso, G. Mocci, A. Orlando, L. Pironi, S. Radice, F. Rizzello, A. Tongiorgi, S. Leone, F. Bossa
JOURNAL OF CROHNS & COLITIS
(2022)
Meeting Abstract
Gastroenterology & Hepatology
A. Costantino, F. Caprioli, M. Vecchi, D. Stocco, M. Aloi, A. Armuzzi, F. Ficari, F. Manguso, G. Mocci, A. Orlando, L. Pironi, S. Radice, F. Rizzello, A. Tongiorgi, S. Leone, F. Bossa
JOURNAL OF CROHNS & COLITIS
(2022)
